Home
Advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML and digital health are transforming our understanding of disease leading to an explosion of new opportunities in drug discovery.
Join us to hear scientific leaders explore how these advances are being used to identify new drug targets and create opportunities for improved pre-clinical work and clinical trials design.
“Outstanding presenters and presentations. Great balance of strategic direction and practical impact. Thought provoking and insightful, and from a number of different perspectives. Quality of presenters, panel discussions, facilitators universally excellent.”
When
29 – 30 APRIL 2024
Welcome dinner and early registration available on Sunday 28 April.
Where
Hinxton Hall Conference Centre
Wellcome Genome Campus
Hinxton, UK. CB10 1RQ
OR online via our conference portal
Registration
Registration is now closed
Abstracts for consideration for poster presentations can be submitted during registration.
Academic discounts available
Keynote speakers
NHS Chair of Pharmacogenetics, University of Liverpool
Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences
Commissioner on Human Medicines (CHM) | UK
CEO, Think 10
Formerly CEO, LifeArc | UK
Key dates 2024
22 January
Early-bird registration opens
1 March
Early bird registration deadline
1 April
Poster Submission closes
18 April
In person registration closes
15 April
Notification of poster acceptance
22 April
Virtual registration closes
Supported by
Our sponsors
AstraZeneca has provided a sponsorship grant towards this independent Programme
About
About
IN-PERSON and ONLINE | 29 – 30 April 2024
Target to Patient conference is returning to Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridge, UK OR online via our dedicated Target to Patient conference web portal.
Both audiences, face-to-face and virtual, will experience presentations from our esteemed panel of speakers, participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials.
This meeting will focus on ground-breaking advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML, digital health, and how they could radically increase the discovery of disease relevant biological targets and the development of new drugs.
Participants from industry, academia and government interested in challenging the existing approaches to target selection and translation are encouraged to attend, and set the agenda for the next era of drug discovery.
Abstracts for consideration for poster presentations can be submitted during registration.
Scientific organising committee
GSK, UK
NPL, UK
GSK, UK
Imperial College London, UK
EMBL-EBI, UK
AstraZeneca, UK
Pfizer, USA
Supported by
Our sponsors
AstraZeneca has provided a sponsorship grant towards this independent Programme
Speakers
Keynote speakers
NHS Chair of Pharmacogenetics, University of Liverpool
Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences
Commissioner on Human Medicines (CHM) | UK
CEO, Think 10
Formerly CEO, LifeArc | UK
Conference speakers | 29 April
Session 1 – Approaches to target selection
Director
Open Targets | UK
Senior Director
GSK Cellzome | Germany
Computational Health Center
HelmholtzAI | Germany
Session 2 – Novel tools and approaches in complex in vitro cellular models
Chief Scientific Officer
Emulate Inc. | UK
Richard Dimbleby Chair of Cancer Research, King’s College London
Vice President and Head of Oncology Translational Research, GSK | UK
Centre for Predictive in vitro Models
Queen Mary University of London | UK
Session 3 – Emerging and re-emerging modalities
Senior Director, Early Oncology
AstraZeneca | UK
Chief Scientific Officer
Proxygen | Austria
Chief Scientific Officer
Arvinas | UK
Conference speakers | 30 April
Session 4 – Risk mitigation strategies
CEO,
Etheros Pharmaceuticals Corp. | UK
Professor for Life Science Management
THI Business School Ingolstadt | Germany
Decision Analyst
GSK, UK
Session 5 – Informatics, computation and AI/ML
Emerging Leader
UK DRI
Head of Cheminformatics & Data Science
GSK | UK
Vice President of AI
BenevolentAI | UK
Programme | Posters
Programme
Poster session
For in-person attendees, the poster sessions will be held on Monday 29 and Tuesday 30 April in the event space. For our virtual attendees, posters will be available to view online via the conference portal.
Abstracts should be submitted during registration.
Deadline for poster submissions: 1 April 2024
Notification of poster acceptance: 15 April 2024
Submission information
- Poster submission is open to all in-person attendees.
- Abstracts should be of your work that are relevant to the topics in the meeting, successful abstracts will be notified by the organising committee.
- A digital copy of your poster submission will be requested if your abstract is accepted and used to display on our online conference platform in advance.
- Poster boards will be available on Sunday 28 April from 16:30 ready for you to display your posters.
- Posters can be left up throughout the conference, until Tuesday 30 April at the end of the conference.
- Please note posters must be taken down by 18:00 on the 30 April.
- For in-person attendees presenting a poster, please note our poster size guidelines: Europe – A0 portrait style, US – 48″ x 36″ portrait style
Registration
Registration
Contact
Contact us
For any questions about the registration process or event logistics, do not hesitate to contact:
Venue information
Venue information
This workshop will be held at: Hinxton Hall Conference Centre, Wellcome Genome Campus, CB10 1RQ.
Set within a one hundred acre estate bordering the River Cam, Hinxton Hall Conference Centre is located on the Wellcome Genome Campus, alongside research institutions that are at the forefront of the genomics revolution.
+44 (0)1223 495123
Registration is now closed. Access to the conference portal has now been sent to all registered attendees attending in person and online, get in touch with us if you have registered but not received the details.
Registration fees
Early bird in person: £225
Early bird virtual: £225
Standard in person: £275
Standard virtual: £275
Student rate: £110*
Academic rate: £150
Conference dinner: £25
*Limited places available, in person attendance only
Amex payments not accepted
Fees include
The full conference programme:
Monday 29 – Tuesday 30 April 2024
Optional welcome dinner and drinks, and early registration on Sunday 28 April (for in person attendees)
Live and recorded presentations
Panel discussions
Live Q&A
poster sessions
Access to our vendor exhibition
Networking opportunities
Access to dedicated on-line conference portal and on-demand materials
Important notes
Registration for delegates attending in person closes 18 April 2024
Registration for delegates attending virtually closes 22 April 2024
Discounts are available for students and delegates from academic organisations
Exhibitors
Exhibitors at Target to Patient
T2P2024 will have an exhibitor’s area integrated into the conference, offering CRO and platform providers the opportunity to engage with the participants at this prestigious conference.
We particularly welcome exhibitors relevant to any of the sessions or the strategic aims of the overall conference, which attracts life scientists from academia, the bitotech/pharma industry and policy makers interested in emerging approaches to drug discovery and deployment for the next decade and beyond.
The exhibitor area is being supported by ELRIG, the leading European not-for-profit organization providing scientific content and exhibition events at life science conferences.
For more, information on exhibitor packages available, please contact Tara Shanks at ELRIG.
Confirmed exhibitors
Supported charity
Supported by
Our sponsors
AstraZeneca has provided a sponsorship grant towards this independent Programme